Podcasts about this peerview live

Go online to PeerView.com/DCG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The time has come for even more precision in testing and targeted treatment of NSCLC. EGFR-mutated lung cancer is a perfect example of this need. The term "EGFR-positive lung cancer” is no longer adequate or specific enough to characterize this complex molecular subtype of lung cancer. Increased granularity is needed for both biomarker testing and targeted treatment selection for patients with different types of EGFR mutations. New agents and combinations have become available for patients with common (eg, exon 19 deletion, exon 21 L858R) and uncommon (eg, exon 20 insertions) EGFR mutations, and more are on the horizon. Novel strategies for overcoming resistance to EGFR-targeted therapies are showing great promise as well. This PeerView Live educational activity, based on a recent live symposium, explores the latest advances and future directions in biomarker-driven, individualized therapy for patients with NSCLC harboring common and less common EGFR mutations through engaging discussions and challenging case-based debates. Upon completion of this activity, participants should be better able to: Characterize the different types of EGFR mutations in NSCLC, their role as therapeutic targets, and evidence supporting the use of current and emerging targeted therapies or combinations for NSCLC with various common or uncommon EGFR mutations; Collaborate with the multidisciplinary team to promote widespread biomarker testing in patients with NSCLC, select appropriate tests to detect common and less common EGFR mutations, and ensure accurate interpretation of results to guide targeted therapy selection; and Apply current evidence and guidelines to individualize targeted therapy for patients with NSCLC exhibiting different EGFR mutations based on the efficacy and safety profile of the therapies, disease characteristics, and patient needs and preferences.

Go online to PeerView.com/DCG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The time has come for even more precision in testing and targeted treatment of NSCLC. EGFR-mutated lung cancer is a perfect example of this need. The term "EGFR-positive lung cancer” is no longer adequate or specific enough to characterize this complex molecular subtype of lung cancer. Increased granularity is needed for both biomarker testing and targeted treatment selection for patients with different types of EGFR mutations. New agents and combinations have become available for patients with common (eg, exon 19 deletion, exon 21 L858R) and uncommon (eg, exon 20 insertions) EGFR mutations, and more are on the horizon. Novel strategies for overcoming resistance to EGFR-targeted therapies are showing great promise as well. This PeerView Live educational activity, based on a recent live symposium, explores the latest advances and future directions in biomarker-driven, individualized therapy for patients with NSCLC harboring common and less common EGFR mutations through engaging discussions and challenging case-based debates. Upon completion of this activity, participants should be better able to: Characterize the different types of EGFR mutations in NSCLC, their role as therapeutic targets, and evidence supporting the use of current and emerging targeted therapies or combinations for NSCLC with various common or uncommon EGFR mutations; Collaborate with the multidisciplinary team to promote widespread biomarker testing in patients with NSCLC, select appropriate tests to detect common and less common EGFR mutations, and ensure accurate interpretation of results to guide targeted therapy selection; and Apply current evidence and guidelines to individualize targeted therapy for patients with NSCLC exhibiting different EGFR mutations based on the efficacy and safety profile of the therapies, disease characteristics, and patient needs and preferences.

Go online to PeerView.com/DCG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The time has come for even more precision in testing and targeted treatment of NSCLC. EGFR-mutated lung cancer is a perfect example of this need. The term "EGFR-positive lung cancer” is no longer adequate or specific enough to characterize this complex molecular subtype of lung cancer. Increased granularity is needed for both biomarker testing and targeted treatment selection for patients with different types of EGFR mutations. New agents and combinations have become available for patients with common (eg, exon 19 deletion, exon 21 L858R) and uncommon (eg, exon 20 insertions) EGFR mutations, and more are on the horizon. Novel strategies for overcoming resistance to EGFR-targeted therapies are showing great promise as well. This PeerView Live educational activity, based on a recent live symposium, explores the latest advances and future directions in biomarker-driven, individualized therapy for patients with NSCLC harboring common and less common EGFR mutations through engaging discussions and challenging case-based debates. Upon completion of this activity, participants should be better able to: Characterize the different types of EGFR mutations in NSCLC, their role as therapeutic targets, and evidence supporting the use of current and emerging targeted therapies or combinations for NSCLC with various common or uncommon EGFR mutations; Collaborate with the multidisciplinary team to promote widespread biomarker testing in patients with NSCLC, select appropriate tests to detect common and less common EGFR mutations, and ensure accurate interpretation of results to guide targeted therapy selection; and Apply current evidence and guidelines to individualize targeted therapy for patients with NSCLC exhibiting different EGFR mutations based on the efficacy and safety profile of the therapies, disease characteristics, and patient needs and preferences.

Go online to PeerView.com/DCG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The time has come for even more precision in testing and targeted treatment of NSCLC. EGFR-mutated lung cancer is a perfect example of this need. The term "EGFR-positive lung cancer” is no longer adequate or specific enough to characterize this complex molecular subtype of lung cancer. Increased granularity is needed for both biomarker testing and targeted treatment selection for patients with different types of EGFR mutations. New agents and combinations have become available for patients with common (eg, exon 19 deletion, exon 21 L858R) and uncommon (eg, exon 20 insertions) EGFR mutations, and more are on the horizon. Novel strategies for overcoming resistance to EGFR-targeted therapies are showing great promise as well. This PeerView Live educational activity, based on a recent live symposium, explores the latest advances and future directions in biomarker-driven, individualized therapy for patients with NSCLC harboring common and less common EGFR mutations through engaging discussions and challenging case-based debates. Upon completion of this activity, participants should be better able to: Characterize the different types of EGFR mutations in NSCLC, their role as therapeutic targets, and evidence supporting the use of current and emerging targeted therapies or combinations for NSCLC with various common or uncommon EGFR mutations; Collaborate with the multidisciplinary team to promote widespread biomarker testing in patients with NSCLC, select appropriate tests to detect common and less common EGFR mutations, and ensure accurate interpretation of results to guide targeted therapy selection; and Apply current evidence and guidelines to individualize targeted therapy for patients with NSCLC exhibiting different EGFR mutations based on the efficacy and safety profile of the therapies, disease characteristics, and patient needs and preferences.

Go online to PeerView.com/DCG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The time has come for even more precision in testing and targeted treatment of NSCLC. EGFR-mutated lung cancer is a perfect example of this need. The term "EGFR-positive lung cancer” is no longer adequate or specific enough to characterize this complex molecular subtype of lung cancer. Increased granularity is needed for both biomarker testing and targeted treatment selection for patients with different types of EGFR mutations. New agents and combinations have become available for patients with common (eg, exon 19 deletion, exon 21 L858R) and uncommon (eg, exon 20 insertions) EGFR mutations, and more are on the horizon. Novel strategies for overcoming resistance to EGFR-targeted therapies are showing great promise as well. This PeerView Live educational activity, based on a recent live symposium, explores the latest advances and future directions in biomarker-driven, individualized therapy for patients with NSCLC harboring common and less common EGFR mutations through engaging discussions and challenging case-based debates. Upon completion of this activity, participants should be better able to: Characterize the different types of EGFR mutations in NSCLC, their role as therapeutic targets, and evidence supporting the use of current and emerging targeted therapies or combinations for NSCLC with various common or uncommon EGFR mutations; Collaborate with the multidisciplinary team to promote widespread biomarker testing in patients with NSCLC, select appropriate tests to detect common and less common EGFR mutations, and ensure accurate interpretation of results to guide targeted therapy selection; and Apply current evidence and guidelines to individualize targeted therapy for patients with NSCLC exhibiting different EGFR mutations based on the efficacy and safety profile of the therapies, disease characteristics, and patient needs and preferences.

Go online to PeerView.com/DCG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The time has come for even more precision in testing and targeted treatment of NSCLC. EGFR-mutated lung cancer is a perfect example of this need. The term "EGFR-positive lung cancer” is no longer adequate or specific enough to characterize this complex molecular subtype of lung cancer. Increased granularity is needed for both biomarker testing and targeted treatment selection for patients with different types of EGFR mutations. New agents and combinations have become available for patients with common (eg, exon 19 deletion, exon 21 L858R) and uncommon (eg, exon 20 insertions) EGFR mutations, and more are on the horizon. Novel strategies for overcoming resistance to EGFR-targeted therapies are showing great promise as well. This PeerView Live educational activity, based on a recent live symposium, explores the latest advances and future directions in biomarker-driven, individualized therapy for patients with NSCLC harboring common and less common EGFR mutations through engaging discussions and challenging case-based debates. Upon completion of this activity, participants should be better able to: Characterize the different types of EGFR mutations in NSCLC, their role as therapeutic targets, and evidence supporting the use of current and emerging targeted therapies or combinations for NSCLC with various common or uncommon EGFR mutations; Collaborate with the multidisciplinary team to promote widespread biomarker testing in patients with NSCLC, select appropriate tests to detect common and less common EGFR mutations, and ensure accurate interpretation of results to guide targeted therapy selection; and Apply current evidence and guidelines to individualize targeted therapy for patients with NSCLC exhibiting different EGFR mutations based on the efficacy and safety profile of the therapies, disease characteristics, and patient needs and preferences.

Go online to PeerView.com/DCG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The time has come for even more precision in testing and targeted treatment of NSCLC. EGFR-mutated lung cancer is a perfect example of this need. The term "EGFR-positive lung cancer” is no longer adequate or specific enough to characterize this complex molecular subtype of lung cancer. Increased granularity is needed for both biomarker testing and targeted treatment selection for patients with different types of EGFR mutations. New agents and combinations have become available for patients with common (eg, exon 19 deletion, exon 21 L858R) and uncommon (eg, exon 20 insertions) EGFR mutations, and more are on the horizon. Novel strategies for overcoming resistance to EGFR-targeted therapies are showing great promise as well. This PeerView Live educational activity, based on a recent live symposium, explores the latest advances and future directions in biomarker-driven, individualized therapy for patients with NSCLC harboring common and less common EGFR mutations through engaging discussions and challenging case-based debates. Upon completion of this activity, participants should be better able to: Characterize the different types of EGFR mutations in NSCLC, their role as therapeutic targets, and evidence supporting the use of current and emerging targeted therapies or combinations for NSCLC with various common or uncommon EGFR mutations; Collaborate with the multidisciplinary team to promote widespread biomarker testing in patients with NSCLC, select appropriate tests to detect common and less common EGFR mutations, and ensure accurate interpretation of results to guide targeted therapy selection; and Apply current evidence and guidelines to individualize targeted therapy for patients with NSCLC exhibiting different EGFR mutations based on the efficacy and safety profile of the therapies, disease characteristics, and patient needs and preferences.

Go online to PeerView.com/DCG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The time has come for even more precision in testing and targeted treatment of NSCLC. EGFR-mutated lung cancer is a perfect example of this need. The term "EGFR-positive lung cancer” is no longer adequate or specific enough to characterize this complex molecular subtype of lung cancer. Increased granularity is needed for both biomarker testing and targeted treatment selection for patients with different types of EGFR mutations. New agents and combinations have become available for patients with common (eg, exon 19 deletion, exon 21 L858R) and uncommon (eg, exon 20 insertions) EGFR mutations, and more are on the horizon. Novel strategies for overcoming resistance to EGFR-targeted therapies are showing great promise as well. This PeerView Live educational activity, based on a recent live symposium, explores the latest advances and future directions in biomarker-driven, individualized therapy for patients with NSCLC harboring common and less common EGFR mutations through engaging discussions and challenging case-based debates. Upon completion of this activity, participants should be better able to: Characterize the different types of EGFR mutations in NSCLC, their role as therapeutic targets, and evidence supporting the use of current and emerging targeted therapies or combinations for NSCLC with various common or uncommon EGFR mutations; Collaborate with the multidisciplinary team to promote widespread biomarker testing in patients with NSCLC, select appropriate tests to detect common and less common EGFR mutations, and ensure accurate interpretation of results to guide targeted therapy selection; and Apply current evidence and guidelines to individualize targeted therapy for patients with NSCLC exhibiting different EGFR mutations based on the efficacy and safety profile of the therapies, disease characteristics, and patient needs and preferences.

Go online to PeerView.com/KCV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Cancer immunotherapy in the form of anti–PD-1, anti–PD-L1, and anti–CTLA-4 monoclonal antibodies is swiftly expanding from metastatic to early-stage, curative-intent settings in an increasing number of solid tumors. Furthermore, it's on the cusp of further explosive growth as other novel agents, including inhibitors of new checkpoints such as LAG-3 and TIGIT, are starting to emerge. Pathologists and oncologists play a crucial role in identifying patients who would benefit the most from the broadening arsenal of immunotherapies and assessing response to these therapies. While there are substantial gaps in biomarker testing, pathologic response assessment, and the use of immunotherapies in current practice, things will only become more complicated. This PeerView Live educational activity, based on a recent symposium, will help you refine your current best practices and prepare you for what's to come next. Top experts convene to provide a visual exploration of the most important recent advances in immuno-oncology, conduct demonstrations of representative and challenging real-world cases, and walk you through practical exercises on operationalizing biomarker testing and pathologic response assessment in different laboratory and clinical settings. Upon completion of this activity, participants should be better able to: Discuss the rationale, recommendations, and practical considerations related to cancer immunotherapy biomarker testing and pathologic response assessment in different tumors and treatment settings, Use appropriate immunotherapy biomarker testing and pathologic response assessment to cancer immunotherapies according to the latest evidence, requirements, and best practice recommendations across different tumors and treatment settings, Implement effective strategies for multidisciplinary communication, collaboration, and coordination among pathologists, oncologists, and other care team professionals regarding selection and interpretation of immunotherapy biomarker tests and pathologic response assessment to guide clinical decision-making regarding cancer immunotherapies across different tumors and treatment settings.

Go online to PeerView.com/KCV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Cancer immunotherapy in the form of anti–PD-1, anti–PD-L1, and anti–CTLA-4 monoclonal antibodies is swiftly expanding from metastatic to early-stage, curative-intent settings in an increasing number of solid tumors. Furthermore, it's on the cusp of further explosive growth as other novel agents, including inhibitors of new checkpoints such as LAG-3 and TIGIT, are starting to emerge. Pathologists and oncologists play a crucial role in identifying patients who would benefit the most from the broadening arsenal of immunotherapies and assessing response to these therapies. While there are substantial gaps in biomarker testing, pathologic response assessment, and the use of immunotherapies in current practice, things will only become more complicated. This PeerView Live educational activity, based on a recent symposium, will help you refine your current best practices and prepare you for what's to come next. Top experts convene to provide a visual exploration of the most important recent advances in immuno-oncology, conduct demonstrations of representative and challenging real-world cases, and walk you through practical exercises on operationalizing biomarker testing and pathologic response assessment in different laboratory and clinical settings. Upon completion of this activity, participants should be better able to: Discuss the rationale, recommendations, and practical considerations related to cancer immunotherapy biomarker testing and pathologic response assessment in different tumors and treatment settings, Use appropriate immunotherapy biomarker testing and pathologic response assessment to cancer immunotherapies according to the latest evidence, requirements, and best practice recommendations across different tumors and treatment settings, Implement effective strategies for multidisciplinary communication, collaboration, and coordination among pathologists, oncologists, and other care team professionals regarding selection and interpretation of immunotherapy biomarker tests and pathologic response assessment to guide clinical decision-making regarding cancer immunotherapies across different tumors and treatment settings.

Go online to PeerView.com/KCV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Cancer immunotherapy in the form of anti–PD-1, anti–PD-L1, and anti–CTLA-4 monoclonal antibodies is swiftly expanding from metastatic to early-stage, curative-intent settings in an increasing number of solid tumors. Furthermore, it's on the cusp of further explosive growth as other novel agents, including inhibitors of new checkpoints such as LAG-3 and TIGIT, are starting to emerge. Pathologists and oncologists play a crucial role in identifying patients who would benefit the most from the broadening arsenal of immunotherapies and assessing response to these therapies. While there are substantial gaps in biomarker testing, pathologic response assessment, and the use of immunotherapies in current practice, things will only become more complicated. This PeerView Live educational activity, based on a recent symposium, will help you refine your current best practices and prepare you for what's to come next. Top experts convene to provide a visual exploration of the most important recent advances in immuno-oncology, conduct demonstrations of representative and challenging real-world cases, and walk you through practical exercises on operationalizing biomarker testing and pathologic response assessment in different laboratory and clinical settings. Upon completion of this activity, participants should be better able to: Discuss the rationale, recommendations, and practical considerations related to cancer immunotherapy biomarker testing and pathologic response assessment in different tumors and treatment settings, Use appropriate immunotherapy biomarker testing and pathologic response assessment to cancer immunotherapies according to the latest evidence, requirements, and best practice recommendations across different tumors and treatment settings, Implement effective strategies for multidisciplinary communication, collaboration, and coordination among pathologists, oncologists, and other care team professionals regarding selection and interpretation of immunotherapy biomarker tests and pathologic response assessment to guide clinical decision-making regarding cancer immunotherapies across different tumors and treatment settings.

Go online to PeerView.com/KCV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Cancer immunotherapy in the form of anti–PD-1, anti–PD-L1, and anti–CTLA-4 monoclonal antibodies is swiftly expanding from metastatic to early-stage, curative-intent settings in an increasing number of solid tumors. Furthermore, it's on the cusp of further explosive growth as other novel agents, including inhibitors of new checkpoints such as LAG-3 and TIGIT, are starting to emerge. Pathologists and oncologists play a crucial role in identifying patients who would benefit the most from the broadening arsenal of immunotherapies and assessing response to these therapies. While there are substantial gaps in biomarker testing, pathologic response assessment, and the use of immunotherapies in current practice, things will only become more complicated. This PeerView Live educational activity, based on a recent symposium, will help you refine your current best practices and prepare you for what's to come next. Top experts convene to provide a visual exploration of the most important recent advances in immuno-oncology, conduct demonstrations of representative and challenging real-world cases, and walk you through practical exercises on operationalizing biomarker testing and pathologic response assessment in different laboratory and clinical settings. Upon completion of this activity, participants should be better able to: Discuss the rationale, recommendations, and practical considerations related to cancer immunotherapy biomarker testing and pathologic response assessment in different tumors and treatment settings, Use appropriate immunotherapy biomarker testing and pathologic response assessment to cancer immunotherapies according to the latest evidence, requirements, and best practice recommendations across different tumors and treatment settings, Implement effective strategies for multidisciplinary communication, collaboration, and coordination among pathologists, oncologists, and other care team professionals regarding selection and interpretation of immunotherapy biomarker tests and pathologic response assessment to guide clinical decision-making regarding cancer immunotherapies across different tumors and treatment settings.

Go online to PeerView.com/KCV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Cancer immunotherapy in the form of anti–PD-1, anti–PD-L1, and anti–CTLA-4 monoclonal antibodies is swiftly expanding from metastatic to early-stage, curative-intent settings in an increasing number of solid tumors. Furthermore, it's on the cusp of further explosive growth as other novel agents, including inhibitors of new checkpoints such as LAG-3 and TIGIT, are starting to emerge. Pathologists and oncologists play a crucial role in identifying patients who would benefit the most from the broadening arsenal of immunotherapies and assessing response to these therapies. While there are substantial gaps in biomarker testing, pathologic response assessment, and the use of immunotherapies in current practice, things will only become more complicated. This PeerView Live educational activity, based on a recent symposium, will help you refine your current best practices and prepare you for what's to come next. Top experts convene to provide a visual exploration of the most important recent advances in immuno-oncology, conduct demonstrations of representative and challenging real-world cases, and walk you through practical exercises on operationalizing biomarker testing and pathologic response assessment in different laboratory and clinical settings. Upon completion of this activity, participants should be better able to: Discuss the rationale, recommendations, and practical considerations related to cancer immunotherapy biomarker testing and pathologic response assessment in different tumors and treatment settings, Use appropriate immunotherapy biomarker testing and pathologic response assessment to cancer immunotherapies according to the latest evidence, requirements, and best practice recommendations across different tumors and treatment settings, Implement effective strategies for multidisciplinary communication, collaboration, and coordination among pathologists, oncologists, and other care team professionals regarding selection and interpretation of immunotherapy biomarker tests and pathologic response assessment to guide clinical decision-making regarding cancer immunotherapies across different tumors and treatment settings.

Go online to PeerView.com/KCV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Cancer immunotherapy in the form of anti–PD-1, anti–PD-L1, and anti–CTLA-4 monoclonal antibodies is swiftly expanding from metastatic to early-stage, curative-intent settings in an increasing number of solid tumors. Furthermore, it's on the cusp of further explosive growth as other novel agents, including inhibitors of new checkpoints such as LAG-3 and TIGIT, are starting to emerge. Pathologists and oncologists play a crucial role in identifying patients who would benefit the most from the broadening arsenal of immunotherapies and assessing response to these therapies. While there are substantial gaps in biomarker testing, pathologic response assessment, and the use of immunotherapies in current practice, things will only become more complicated. This PeerView Live educational activity, based on a recent symposium, will help you refine your current best practices and prepare you for what's to come next. Top experts convene to provide a visual exploration of the most important recent advances in immuno-oncology, conduct demonstrations of representative and challenging real-world cases, and walk you through practical exercises on operationalizing biomarker testing and pathologic response assessment in different laboratory and clinical settings. Upon completion of this activity, participants should be better able to: Discuss the rationale, recommendations, and practical considerations related to cancer immunotherapy biomarker testing and pathologic response assessment in different tumors and treatment settings, Use appropriate immunotherapy biomarker testing and pathologic response assessment to cancer immunotherapies according to the latest evidence, requirements, and best practice recommendations across different tumors and treatment settings, Implement effective strategies for multidisciplinary communication, collaboration, and coordination among pathologists, oncologists, and other care team professionals regarding selection and interpretation of immunotherapy biomarker tests and pathologic response assessment to guide clinical decision-making regarding cancer immunotherapies across different tumors and treatment settings.

Go online to PeerView.com/KCV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Cancer immunotherapy in the form of anti–PD-1, anti–PD-L1, and anti–CTLA-4 monoclonal antibodies is swiftly expanding from metastatic to early-stage, curative-intent settings in an increasing number of solid tumors. Furthermore, it's on the cusp of further explosive growth as other novel agents, including inhibitors of new checkpoints such as LAG-3 and TIGIT, are starting to emerge. Pathologists and oncologists play a crucial role in identifying patients who would benefit the most from the broadening arsenal of immunotherapies and assessing response to these therapies. While there are substantial gaps in biomarker testing, pathologic response assessment, and the use of immunotherapies in current practice, things will only become more complicated. This PeerView Live educational activity, based on a recent symposium, will help you refine your current best practices and prepare you for what's to come next. Top experts convene to provide a visual exploration of the most important recent advances in immuno-oncology, conduct demonstrations of representative and challenging real-world cases, and walk you through practical exercises on operationalizing biomarker testing and pathologic response assessment in different laboratory and clinical settings. Upon completion of this activity, participants should be better able to: Discuss the rationale, recommendations, and practical considerations related to cancer immunotherapy biomarker testing and pathologic response assessment in different tumors and treatment settings, Use appropriate immunotherapy biomarker testing and pathologic response assessment to cancer immunotherapies according to the latest evidence, requirements, and best practice recommendations across different tumors and treatment settings, Implement effective strategies for multidisciplinary communication, collaboration, and coordination among pathologists, oncologists, and other care team professionals regarding selection and interpretation of immunotherapy biomarker tests and pathologic response assessment to guide clinical decision-making regarding cancer immunotherapies across different tumors and treatment settings.

Go online to PeerView.com/KCV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Cancer immunotherapy in the form of anti–PD-1, anti–PD-L1, and anti–CTLA-4 monoclonal antibodies is swiftly expanding from metastatic to early-stage, curative-intent settings in an increasing number of solid tumors. Furthermore, it's on the cusp of further explosive growth as other novel agents, including inhibitors of new checkpoints such as LAG-3 and TIGIT, are starting to emerge. Pathologists and oncologists play a crucial role in identifying patients who would benefit the most from the broadening arsenal of immunotherapies and assessing response to these therapies. While there are substantial gaps in biomarker testing, pathologic response assessment, and the use of immunotherapies in current practice, things will only become more complicated. This PeerView Live educational activity, based on a recent symposium, will help you refine your current best practices and prepare you for what's to come next. Top experts convene to provide a visual exploration of the most important recent advances in immuno-oncology, conduct demonstrations of representative and challenging real-world cases, and walk you through practical exercises on operationalizing biomarker testing and pathologic response assessment in different laboratory and clinical settings. Upon completion of this activity, participants should be better able to: Discuss the rationale, recommendations, and practical considerations related to cancer immunotherapy biomarker testing and pathologic response assessment in different tumors and treatment settings, Use appropriate immunotherapy biomarker testing and pathologic response assessment to cancer immunotherapies according to the latest evidence, requirements, and best practice recommendations across different tumors and treatment settings, Implement effective strategies for multidisciplinary communication, collaboration, and coordination among pathologists, oncologists, and other care team professionals regarding selection and interpretation of immunotherapy biomarker tests and pathologic response assessment to guide clinical decision-making regarding cancer immunotherapies across different tumors and treatment settings.

Go online to PeerView.com/KCV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Cancer immunotherapy in the form of anti–PD-1, anti–PD-L1, and anti–CTLA-4 monoclonal antibodies is swiftly expanding from metastatic to early-stage, curative-intent settings in an increasing number of solid tumors. Furthermore, it's on the cusp of further explosive growth as other novel agents, including inhibitors of new checkpoints such as LAG-3 and TIGIT, are starting to emerge. Pathologists and oncologists play a crucial role in identifying patients who would benefit the most from the broadening arsenal of immunotherapies and assessing response to these therapies. While there are substantial gaps in biomarker testing, pathologic response assessment, and the use of immunotherapies in current practice, things will only become more complicated. This PeerView Live educational activity, based on a recent symposium, will help you refine your current best practices and prepare you for what's to come next. Top experts convene to provide a visual exploration of the most important recent advances in immuno-oncology, conduct demonstrations of representative and challenging real-world cases, and walk you through practical exercises on operationalizing biomarker testing and pathologic response assessment in different laboratory and clinical settings. Upon completion of this activity, participants should be better able to: Discuss the rationale, recommendations, and practical considerations related to cancer immunotherapy biomarker testing and pathologic response assessment in different tumors and treatment settings, Use appropriate immunotherapy biomarker testing and pathologic response assessment to cancer immunotherapies according to the latest evidence, requirements, and best practice recommendations across different tumors and treatment settings, Implement effective strategies for multidisciplinary communication, collaboration, and coordination among pathologists, oncologists, and other care team professionals regarding selection and interpretation of immunotherapy biomarker tests and pathologic response assessment to guide clinical decision-making regarding cancer immunotherapies across different tumors and treatment settings.

Go online to PeerView.com/KCV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Cancer immunotherapy in the form of anti–PD-1, anti–PD-L1, and anti–CTLA-4 monoclonal antibodies is swiftly expanding from metastatic to early-stage, curative-intent settings in an increasing number of solid tumors. Furthermore, it's on the cusp of further explosive growth as other novel agents, including inhibitors of new checkpoints such as LAG-3 and TIGIT, are starting to emerge. Pathologists and oncologists play a crucial role in identifying patients who would benefit the most from the broadening arsenal of immunotherapies and assessing response to these therapies. While there are substantial gaps in biomarker testing, pathologic response assessment, and the use of immunotherapies in current practice, things will only become more complicated. This PeerView Live educational activity, based on a recent symposium, will help you refine your current best practices and prepare you for what's to come next. Top experts convene to provide a visual exploration of the most important recent advances in immuno-oncology, conduct demonstrations of representative and challenging real-world cases, and walk you through practical exercises on operationalizing biomarker testing and pathologic response assessment in different laboratory and clinical settings. Upon completion of this activity, participants should be better able to: Discuss the rationale, recommendations, and practical considerations related to cancer immunotherapy biomarker testing and pathologic response assessment in different tumors and treatment settings, Use appropriate immunotherapy biomarker testing and pathologic response assessment to cancer immunotherapies according to the latest evidence, requirements, and best practice recommendations across different tumors and treatment settings, Implement effective strategies for multidisciplinary communication, collaboration, and coordination among pathologists, oncologists, and other care team professionals regarding selection and interpretation of immunotherapy biomarker tests and pathologic response assessment to guide clinical decision-making regarding cancer immunotherapies across different tumors and treatment settings.

Go online to PeerView.com/KFC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Advances in the management of patients with EGFR-mutated non-small cell lung cancer (NSCLC) have set a precedent for precision medicine. Genomic testing for EGFR mutations and use of EGFR-targeted therapies in appropriate patients have had an established role in the metastatic setting for many years, and they have recently expanded to early-stage disease. Based on impressive data, the FDA granted approval for the first EGFR tyrosine kinase inhibitor as adjuvant therapy following tumor resection in patients with NSCLC whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test. This approval has effectively changed the standard of care in the early-stage setting, with implications for the practice of the entire multidisciplinary team. This PeerView Live educational activity based on a recent web broadcast provides expert insights on the latest data and useful guidance for navigating the controversies, complexities of decision-making, and practicalities of multidisciplinary collaboration related to EGFR testing and EGFR-targeted therapy in early-stage NSCLC. Upon completion of this activity, participants should be better able to: Discuss the molecular heterogeneity of NSCLC and the oncogenic drivers such as EGFR mutations that help to inform treatment decisions regarding targeted therapies, Evaluate the latest safety and efficacy data on EGFR-targeted therapies in patients with early-stage EGFR-mutated NSCLC, Describe the evolving evidence and best practices for EGFR testing in lung cancer, including in early-stage NSCLC, Collaborate with the multidisciplinary team to integrate EGFR-targeted therapy into treatment plans for eligible patients with EGFR-mutated NSCLC, including in the adjuvant setting, according to recent evidence, precision oncology principles, and patient needs and preferences.

Go online to PeerView.com/KFC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Advances in the management of patients with EGFR-mutated non-small cell lung cancer (NSCLC) have set a precedent for precision medicine. Genomic testing for EGFR mutations and use of EGFR-targeted therapies in appropriate patients have had an established role in the metastatic setting for many years, and they have recently expanded to early-stage disease. Based on impressive data, the FDA granted approval for the first EGFR tyrosine kinase inhibitor as adjuvant therapy following tumor resection in patients with NSCLC whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test. This approval has effectively changed the standard of care in the early-stage setting, with implications for the practice of the entire multidisciplinary team. This PeerView Live educational activity based on a recent web broadcast provides expert insights on the latest data and useful guidance for navigating the controversies, complexities of decision-making, and practicalities of multidisciplinary collaboration related to EGFR testing and EGFR-targeted therapy in early-stage NSCLC. Upon completion of this activity, participants should be better able to: Discuss the molecular heterogeneity of NSCLC and the oncogenic drivers such as EGFR mutations that help to inform treatment decisions regarding targeted therapies, Evaluate the latest safety and efficacy data on EGFR-targeted therapies in patients with early-stage EGFR-mutated NSCLC, Describe the evolving evidence and best practices for EGFR testing in lung cancer, including in early-stage NSCLC, Collaborate with the multidisciplinary team to integrate EGFR-targeted therapy into treatment plans for eligible patients with EGFR-mutated NSCLC, including in the adjuvant setting, according to recent evidence, precision oncology principles, and patient needs and preferences.

Go online to PeerView.com/KFC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Advances in the management of patients with EGFR-mutated non-small cell lung cancer (NSCLC) have set a precedent for precision medicine. Genomic testing for EGFR mutations and use of EGFR-targeted therapies in appropriate patients have had an established role in the metastatic setting for many years, and they have recently expanded to early-stage disease. Based on impressive data, the FDA granted approval for the first EGFR tyrosine kinase inhibitor as adjuvant therapy following tumor resection in patients with NSCLC whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test. This approval has effectively changed the standard of care in the early-stage setting, with implications for the practice of the entire multidisciplinary team. This PeerView Live educational activity based on a recent web broadcast provides expert insights on the latest data and useful guidance for navigating the controversies, complexities of decision-making, and practicalities of multidisciplinary collaboration related to EGFR testing and EGFR-targeted therapy in early-stage NSCLC. Upon completion of this activity, participants should be better able to: Discuss the molecular heterogeneity of NSCLC and the oncogenic drivers such as EGFR mutations that help to inform treatment decisions regarding targeted therapies, Evaluate the latest safety and efficacy data on EGFR-targeted therapies in patients with early-stage EGFR-mutated NSCLC, Describe the evolving evidence and best practices for EGFR testing in lung cancer, including in early-stage NSCLC, Collaborate with the multidisciplinary team to integrate EGFR-targeted therapy into treatment plans for eligible patients with EGFR-mutated NSCLC, including in the adjuvant setting, according to recent evidence, precision oncology principles, and patient needs and preferences.

Go online to PeerView.com/KFC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Advances in the management of patients with EGFR-mutated non-small cell lung cancer (NSCLC) have set a precedent for precision medicine. Genomic testing for EGFR mutations and use of EGFR-targeted therapies in appropriate patients have had an established role in the metastatic setting for many years, and they have recently expanded to early-stage disease. Based on impressive data, the FDA granted approval for the first EGFR tyrosine kinase inhibitor as adjuvant therapy following tumor resection in patients with NSCLC whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test. This approval has effectively changed the standard of care in the early-stage setting, with implications for the practice of the entire multidisciplinary team. This PeerView Live educational activity based on a recent web broadcast provides expert insights on the latest data and useful guidance for navigating the controversies, complexities of decision-making, and practicalities of multidisciplinary collaboration related to EGFR testing and EGFR-targeted therapy in early-stage NSCLC. Upon completion of this activity, participants should be better able to: Discuss the molecular heterogeneity of NSCLC and the oncogenic drivers such as EGFR mutations that help to inform treatment decisions regarding targeted therapies, Evaluate the latest safety and efficacy data on EGFR-targeted therapies in patients with early-stage EGFR-mutated NSCLC, Describe the evolving evidence and best practices for EGFR testing in lung cancer, including in early-stage NSCLC, Collaborate with the multidisciplinary team to integrate EGFR-targeted therapy into treatment plans for eligible patients with EGFR-mutated NSCLC, including in the adjuvant setting, according to recent evidence, precision oncology principles, and patient needs and preferences.

Go online to PeerView.com/KFC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Advances in the management of patients with EGFR-mutated non-small cell lung cancer (NSCLC) have set a precedent for precision medicine. Genomic testing for EGFR mutations and use of EGFR-targeted therapies in appropriate patients have had an established role in the metastatic setting for many years, and they have recently expanded to early-stage disease. Based on impressive data, the FDA granted approval for the first EGFR tyrosine kinase inhibitor as adjuvant therapy following tumor resection in patients with NSCLC whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test. This approval has effectively changed the standard of care in the early-stage setting, with implications for the practice of the entire multidisciplinary team. This PeerView Live educational activity based on a recent web broadcast provides expert insights on the latest data and useful guidance for navigating the controversies, complexities of decision-making, and practicalities of multidisciplinary collaboration related to EGFR testing and EGFR-targeted therapy in early-stage NSCLC. Upon completion of this activity, participants should be better able to: Discuss the molecular heterogeneity of NSCLC and the oncogenic drivers such as EGFR mutations that help to inform treatment decisions regarding targeted therapies, Evaluate the latest safety and efficacy data on EGFR-targeted therapies in patients with early-stage EGFR-mutated NSCLC, Describe the evolving evidence and best practices for EGFR testing in lung cancer, including in early-stage NSCLC, Collaborate with the multidisciplinary team to integrate EGFR-targeted therapy into treatment plans for eligible patients with EGFR-mutated NSCLC, including in the adjuvant setting, according to recent evidence, precision oncology principles, and patient needs and preferences.

Go online to PeerView.com/KFC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Advances in the management of patients with EGFR-mutated non-small cell lung cancer (NSCLC) have set a precedent for precision medicine. Genomic testing for EGFR mutations and use of EGFR-targeted therapies in appropriate patients have had an established role in the metastatic setting for many years, and they have recently expanded to early-stage disease. Based on impressive data, the FDA granted approval for the first EGFR tyrosine kinase inhibitor as adjuvant therapy following tumor resection in patients with NSCLC whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test. This approval has effectively changed the standard of care in the early-stage setting, with implications for the practice of the entire multidisciplinary team. This PeerView Live educational activity based on a recent web broadcast provides expert insights on the latest data and useful guidance for navigating the controversies, complexities of decision-making, and practicalities of multidisciplinary collaboration related to EGFR testing and EGFR-targeted therapy in early-stage NSCLC. Upon completion of this activity, participants should be better able to: Discuss the molecular heterogeneity of NSCLC and the oncogenic drivers such as EGFR mutations that help to inform treatment decisions regarding targeted therapies, Evaluate the latest safety and efficacy data on EGFR-targeted therapies in patients with early-stage EGFR-mutated NSCLC, Describe the evolving evidence and best practices for EGFR testing in lung cancer, including in early-stage NSCLC, Collaborate with the multidisciplinary team to integrate EGFR-targeted therapy into treatment plans for eligible patients with EGFR-mutated NSCLC, including in the adjuvant setting, according to recent evidence, precision oncology principles, and patient needs and preferences.

Go online to PeerView.com/KFC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Advances in the management of patients with EGFR-mutated non-small cell lung cancer (NSCLC) have set a precedent for precision medicine. Genomic testing for EGFR mutations and use of EGFR-targeted therapies in appropriate patients have had an established role in the metastatic setting for many years, and they have recently expanded to early-stage disease. Based on impressive data, the FDA granted approval for the first EGFR tyrosine kinase inhibitor as adjuvant therapy following tumor resection in patients with NSCLC whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test. This approval has effectively changed the standard of care in the early-stage setting, with implications for the practice of the entire multidisciplinary team. This PeerView Live educational activity based on a recent web broadcast provides expert insights on the latest data and useful guidance for navigating the controversies, complexities of decision-making, and practicalities of multidisciplinary collaboration related to EGFR testing and EGFR-targeted therapy in early-stage NSCLC. Upon completion of this activity, participants should be better able to: Discuss the molecular heterogeneity of NSCLC and the oncogenic drivers such as EGFR mutations that help to inform treatment decisions regarding targeted therapies, Evaluate the latest safety and efficacy data on EGFR-targeted therapies in patients with early-stage EGFR-mutated NSCLC, Describe the evolving evidence and best practices for EGFR testing in lung cancer, including in early-stage NSCLC, Collaborate with the multidisciplinary team to integrate EGFR-targeted therapy into treatment plans for eligible patients with EGFR-mutated NSCLC, including in the adjuvant setting, according to recent evidence, precision oncology principles, and patient needs and preferences.

Go online to PeerView.com/KFC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Advances in the management of patients with EGFR-mutated non-small cell lung cancer (NSCLC) have set a precedent for precision medicine. Genomic testing for EGFR mutations and use of EGFR-targeted therapies in appropriate patients have had an established role in the metastatic setting for many years, and they have recently expanded to early-stage disease. Based on impressive data, the FDA granted approval for the first EGFR tyrosine kinase inhibitor as adjuvant therapy following tumor resection in patients with NSCLC whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test. This approval has effectively changed the standard of care in the early-stage setting, with implications for the practice of the entire multidisciplinary team. This PeerView Live educational activity based on a recent web broadcast provides expert insights on the latest data and useful guidance for navigating the controversies, complexities of decision-making, and practicalities of multidisciplinary collaboration related to EGFR testing and EGFR-targeted therapy in early-stage NSCLC. Upon completion of this activity, participants should be better able to: Discuss the molecular heterogeneity of NSCLC and the oncogenic drivers such as EGFR mutations that help to inform treatment decisions regarding targeted therapies, Evaluate the latest safety and efficacy data on EGFR-targeted therapies in patients with early-stage EGFR-mutated NSCLC, Describe the evolving evidence and best practices for EGFR testing in lung cancer, including in early-stage NSCLC, Collaborate with the multidisciplinary team to integrate EGFR-targeted therapy into treatment plans for eligible patients with EGFR-mutated NSCLC, including in the adjuvant setting, according to recent evidence, precision oncology principles, and patient needs and preferences.